 No-Observed-Adverse-Effect Level
"No-Observed-Adverse-Effect Level" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The highest dosage administered that does not produce toxic effects.
| Descriptor ID |
D019055
|
| MeSH Number(s) |
E05.940.600 G07.690.936.750
|
| Concept/Terms |
No-Observed-Adverse-Effect Level- No-Observed-Adverse-Effect Level
- Level, No-Observed-Adverse-Effect
- Levels, No-Observed-Adverse-Effect
- No Observed Adverse Effect Level
- No-Observed-Adverse-Effect Levels
- NOAEL
No-Observed-Effect Level- No-Observed-Effect Level
- Level, No-Observed-Effect
- Levels, No-Observed-Effect
- No Observed Effect Level
- No-Observed-Effect Levels
Acceptable Daily Intake- Acceptable Daily Intake
- Acceptable Daily Intakes
- Daily Intake, Acceptable
- Daily Intakes, Acceptable
- Intake, Acceptable Daily
- Intakes, Acceptable Daily
- Tolerable Daily Intake
- Daily Intake, Tolerable
- Daily Intakes, Tolerable
- Intake, Tolerable Daily
- Intakes, Tolerable Daily
- Tolerable Daily Intakes
|
Below are MeSH descriptors whose meaning is more general than "No-Observed-Adverse-Effect Level".
Below are MeSH descriptors whose meaning is more specific than "No-Observed-Adverse-Effect Level".
This graph shows the total number of publications written about "No-Observed-Adverse-Effect Level" by people in this website by year, and whether "No-Observed-Adverse-Effect Level" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "No-Observed-Adverse-Effect Level" by people in Profiles.
-
Westerhout J, Baumert JL, Blom WM, Allen KJ, Ballmer-Weber B, Crevel RWR, Dubois AEJ, Fern?ndez-Rivas M, Greenhawt MJ, Hourihane JO, Koplin JJ, Kruizinga AG, Le TM, Sampson HA, Shreffler WG, Turner PJ, Taylor SL, Houben GF, Remington BC. Deriving individual threshold doses from clinical food challenge data for population risk assessment of food allergens. J Allergy Clin Immunol. 2019 11; 144(5):1290-1309.
-
Zu K, Pizzurro DM, Lewandowski TA, Goodman JE. Pharmacokinetic data reduce uncertainty in the acceptable daily intake for benzoic acid and its salts. Regul Toxicol Pharmacol. 2017 Oct; 89:83-94.
-
Gad SC, Sullivan DW, Crapo JD, Spainhour CB. A nonclinical safety assessment of MnTE-2-PyP, a manganese porphyrin. Int J Toxicol. 2013 Jul; 32(4):274-87.
-
Bailey LA, Goodman JE, Beck BD. Proposal for a revised Reference Concentration (RfC) for manganese based on recent epidemiological studies. Regul Toxicol Pharmacol. 2009 Dec; 55(3):330-9.
-
Sen M, Tosca PJ, Zwayer C, Ryan MJ, Johnson JD, Knostman KA, Giclas PC, Peggins JO, Tomaszewski JE, McMurray TP, Li C, Leibowitz MS, Ferris RL, Gooding WE, Thomas SM, Johnson DE, Grandis JR. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2009 May; 63(6):983-95.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|